These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135 [Abstract] [Full Text] [Related]
4. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Rascol O, Bronzova J, Hauser RA, Lang AE, Sampaio C, Theeuwes A, van de Witte SV. Parkinsonism Relat Disord; 2012 May; 18(4):370-6. PubMed ID: 22316635 [Abstract] [Full Text] [Related]
8. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Mov Disord; 2010 Jul 30; 25(10):1357-63. PubMed ID: 20198649 [Abstract] [Full Text] [Related]
9. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA. Br J Clin Pharmacol; 2004 Nov 30; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [Abstract] [Full Text] [Related]
10. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. Im JH, Ha JH, Cho IS, Lee MC. J Neurol; 2003 Jan 30; 250(1):90-6. PubMed ID: 12527999 [Abstract] [Full Text] [Related]
11. Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Wolz M, Löhle M, Strecker K, Schwanebeck U, Schneider C, Reichmann H, Grählert X, Schwarz J, Storch A. J Neural Transm (Vienna); 2010 Nov 30; 117(11):1279-86. PubMed ID: 20803300 [Abstract] [Full Text] [Related]
12. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. Mov Disord; 2007 Jan 15; 22(2):179-86. PubMed ID: 17094088 [Abstract] [Full Text] [Related]
14. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C. Mov Disord; 2013 Nov 15; 28(13):1838-46. PubMed ID: 23853029 [Abstract] [Full Text] [Related]
15. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O, NS-Park CIC Network. Neurology; 2014 Jan 28; 82(4):300-7. PubMed ID: 24371304 [Abstract] [Full Text] [Related]
16. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE. Mov Disord; 2007 Dec 28; 22(16):2409-17. PubMed ID: 17894339 [Abstract] [Full Text] [Related]
18. A trial of dextromethorphan in parkinsonian patients with motor response complications. Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natté R, Chase TN. Mov Disord; 1998 May 28; 13(3):414-7. PubMed ID: 9613730 [Abstract] [Full Text] [Related]